Future research should delve deeper into these relationships to develop more personalized treatment strategies based on IL-1β expression and other biomarkers, while emphasizing the complex role of IL-1β in NSCLC and its interaction with different treatments. The gene discussed is IL1B; the disease is non-small cell lung carcinoma.